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Background: Carbapenemase-producing Enterobacteriaceae represent an increasing threat to public health and
to the treatment of serious nosocomial infections. The aim of this study was to screen for the presence of
carbapenemase-producing Enterobacteriaceae in human carriers in community settings in Switzerland, a country
representative of central Europe.
Findings: Three hundred and fourteen stool samples of healthy staff members of a meat-processing company and
291 fecal swabs from primary care patients were recovered in Switzerland between April 2012 and July 2012 and
were tested for carbapenemase-producing Enterobacteriaceae isolates by selecting for growth on a carbapenem-
containing selective medium. Six resulting isolates (5 Escherichia coli and 1 Citrobacter youngae) were subjected to
antimicrobial susceptibility tests and PCR analysis by screening for the carbapenemase genes blaOXA-48, blaVIM,
blaNDM-1, and blaKPC as well as for the extended-spectrum ß-lactamase genes blaTEM, blaSHV, blaCTX-M and
blaCMY-2. No carbapenemase genes were detected. Resistance to ß-lactam antibiotics was due to carriage of the
extended-spectrum ß-lactamase CTX-M-15 in 4 isolates, to CTX-M-14 in one further isolate and to the plasmidic
AmpC-ß-lactamase CMY-2 in one isolate.
Conclusions: These results show that carbapenemase-producing Enterobacteriaceae are as yet not present in the
community. Continuous surveillance is necessary to anticipate future trends in the prevalence and dissemination of
carbapenem resistant isolates in the population.
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The emergence and worldwide spread of carbapenemase
producing Enterobacteriaceae is of great concern to pub-
lic health services and a major threat to the efficacy of
carbapenem antibiotics such as imipenem, ertapenem or
meropenem, which are drugs of choice for the treatment
of infections due to extended-spectrum ß-lactamase
(ESBL)-producing strains [1].
Currently globally disseminating carbapenem hydrolysing
ß-lactamases include the Ambler Class A carbapenemase
KPC, the Ambler class B metallo-ß-lactamases (MBLs)
such as the IMP-, the VIM- or the NDM-type carba-
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of carbapenemase-producing Enterobacteriaceae, (especially
Klebsiella pneumoniae) in European countries follows a
pattern typical for hospital-acquired pathogens, and the
spread from hospital to community settings is hence a
matter of time, as demonstrated in the past by the disse-
mination of ESBL-producers [4]. Due to the variability of
resistance levels to carbapenem antibiotics, carbapenemase-
producers cannot be easily detected. Thus, the actual preva-
lence in the community remains unknown and possibly
even underestimated [3].
The aim of the present study was therefore to screen
for the presence of carbapenemase-producing Entero-
bacteriaceae in human carriers in a non-hospital setting
in Switzerland.
Switzerland, a country with a restrictive antibiotic
policy [5], lies not only at a geographical center, but alsoed Central Ltd. This is an Open Access article distributed under the terms of
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miological intersection in the center of Europe, where
differences between linguistic regions reflect the differ-
ences observed between surrounding European coun-
tries [6]. This makes the country ideal for monitoring
temporal-spacial trends in antibiotic resistance in central
Europe.
KPC-carbapenemases in K. pneumoniae was first
reported in a hospital in Switzerland in 2010 [7] attri-
buted to travel-related importation from Italy, followed
by four further cases introduced to Switzerland, from
hospitalized patients initially treated in Italy and Greece
[8]. NDM producing isolates were first reported in
Geneva in 2011 [9] and related to travel importation
from the Balkans and the Indian subcontinent. In 2012,
Oxa-48 producers were identified in Switzerland [10].
Our aim was to determine whether or not, carbapene-
mase producers have spread beyond the hospital setting.
In an ongoing study of routine stool samples from
healthy factory staff and a study on ESBL-producing
Enterobacteriaceae in fecal swabs of primary care pa-
tients [11], 314 stool samples and 291 fecal swabs were
obtained and incubated for 24 hours at 37°C in 10 ml of
Enterobacteriaceae Enrichment (EE) broth (BD, Franklin
Lakes, USA) to enhance the recovery of Enterobacte-
riaceae. One loopful each of the enrichment cultures
was inoculated onto chromogenic Brilliance CRE agar
(Oxoid, Hampshire, UK) containing a carbapenem to se-
lect for carbapenemase producers. Pink colonies (E. coli)
and blue colonies (Klebsiella, Enterobacter, Serratia and
Citrobacter spp.) were selected for further analysis.
Otherwise pigmented or white colonies were discarded.
In total, 6 isolates were collected. Three E coli isolates
from the 314 stool samples, one C. youngae and 2 E. coli
isolates from the 291 fecal swab samples were identified
using the API ID 32 E test (bioMérieux, Marcy l′Etoile,
France) and screened by PCR for the presence of
blaOXA-48, blaVIM, blaNDM-1, and blaKPC, using primers
described previously [12,13] and using DNA isolated
from strains IMMZH201261080, IMMZH201165843,
IMMZH201163819 and IMMZH63372-3 as positive
controls, respectively (kindly provided by Dr. Guido
Bloemberg, Institute of Medical Microbiology, Zürich).
The minimal inhibitory concentration of imipenem for
the six isolates was performed using Etest IP strips
(bioMérieux, Marcy l′Etoile, France), according to the
Clinical and Laboratory Standards Institute [14].
No carbapenemase genes were detected in the analysed
isolates. Resistance levels to imipenem remained for all
isolates below the susceptibility breakpoint of the new in-
terpretive criteria implemented by the CLSI [14], minimal
inhibitory concentrations ranging between 0.125 μg/ml
and 0.25 μg/ml. Further susceptibility testing per-
formed by disk diffusion assay, using antibiotic disks(Becton Dickinson and Company, Maryland, USA) re-
vealed an ESBL phenotype for 5 of the 6 isolates and
an AmpC phenotype for one isolate (data not shown).
PCR using appropriate primers [15-17] revealed the
presence of the extended-spectrum ß-lactamase CTX-M-
15 in 4 isolates, CTX-M-14 in one, and the plasmidic
AmpC-type ß-lactamase CMY-2 in a further isolate.
Taking into consideration the possibility of reduced
carbapenem susceptibility caused by alterations of outer
membrane proteins in combination with an ESBL- or an
AmpC-type enzyme as decribed previously [18,19], these
results offer an explanation for the initial growth of these
isolates on the selective medium.
In conclusion, our study testifies the current ab-
sence of carbapenemase-producers in healthy people
and primary care patients in Switzerland, indicating
that carbapenemase-producers have not entered the
community in this country. Additional studies should
be carried out in future in order to continuously evaluate
the dissemination of carbapenemase-producers among
enteric bacteria in the population, including screening of
patients transferred from hospitals from countries where
carbapenemase-producers have been detected. Utmost
care should be taken to minimize the impact of the emer-
ging crisis of carbapenem resistant Enterobacteriaceae.
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